WILMINGTON, Del., March 09, 2022 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) a clinical-stage precision oncology company, today announced that...
Strong revenue growth of 46% for the fourth quarter and 32% for full year 2021 Full year 2022 revenue expected...
SOUTH SAN FRANCISCO, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a...
CAMBRIDGE, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a...
Data to be presented at the 2022 annual meeting of American Association for Cancer ResearchMILAN, Italy and NEW YORK, March...
On track to complete dosing of the first cohort and share initial data by the end of the first half...
GATINEAU, Quebec, March 09, 2022 (GLOBE NEWSWIRE) -- HEXO Corp. (TSX: HEXO; NASDAQ: HEXO) (“HEXO”), a leading producer of high-quality...
OCALA, Fla., March 09, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma...
Broad-acting antihistamine has potential in number of disease areas with unmet clinical needNEW YORK and LONDON, March 09, 2022 (GLOBE...
- Phase 1 Study of TARA-002 in Patients with Non-Muscle Invasive Bladder Cancer Under Way - - Strong Cash Position...
Revenue Growth of 34% in 2021, with Record Quarterly and Annual Revenues Continued Progress in Expanding FDA Labeling for Deep...
Pipeline of Development-Stage RAS(ON) Inhibitors to be Highlighted in Four Presentations in “Targeting the RAS Oncogene” Session, as well as...
MALVERN, Pa., March 09, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing,...
OCALA, Fla., March 09, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma...
New structure replaces existing facility with a significant interest rate reduction resulting in approximately $2.8 million of annualized interest savingsWATERTOWN,...
myIntelX will be launching in conjunction with KidneyIntelX going live at Atrium Health, and will expand testing services across all...
Amryt Announces 22% growth in FY 2021 Revenues to $222.5M Issuing FY 2022 revenue guidance of $260M - $270M, representing...
The company reiterates full year 2022 guidanceSEATTLE, March 09, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial-stage...
NEW YORK, March 09, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...
Toronto, Ontario--(Newsfile Corp. - March 9, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a...
